Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coal tar

Executive Summary

California Prop 65 trial over use of coal tar in dandruff shampoos and other OTCs stayed until Jan. 29. Consolidated trial in separate lawsuits brought by the state and Perry Gottesfeld had been slated to begin Oct. 10, but defendants Bergen Brunswig and Reedco requested a stay pending FDA review of the ingredient's safety (1"The Rose Sheet" Sept. 4, p. 7). Defendants include J&J's Neutrogena division and Denorex shampoo marketer Whitehall-Robins. Reedco is a subsidiary of Tegrin maker Block Drug, which SmithKline Beecham is acquiring for roughly $1.24 bil
Advertisement

Related Content

OTC Coal Tar Skin Cancer Causation Data Lacking - FDA
OTC Coal Tar Skin Cancer Causation Data Lacking - FDA
California Coal Tar Litigation Stay Sought Pending FDA Petition Review
California Coal Tar Litigation Stay Sought Pending FDA Petition Review
Advertisement
UsernamePublicRestriction

Register

RS008578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel